PreveCeutical Medical Inc. announced that it has started preparations to accelerate completion of its preclinical dual gene therapy program using developed and in vitro validated Smart-siRNA sequences, which when paired with proprietary biore sponsorive lipid-nanoparticulate delivery systems effectively target the PTPN1 gene. PreveCeutical has received direct interest in diabetes & obesity dual gene therapy program from a pharmaceutical company established in the diabetes and obesity therapeutic space. Explicit interest in gene target has been expressed while also requesting the completion of gene-protein silencing efficacy and safety evaluation studies in rodent disease models, employing lead Smart-siRNA bio-responsive carrier systems. Completing the planned proof-of-concept preclinical studies will enable PreveCeutical and the potential pharmaceutical partner to evaluate the next steps toward developing a commercial product for clinical trials.

To address the global rise of diabetes and obesity, and in furtherance of PreveCeutical's preventive health care focus, the Research Program builds on years of multi-disciplinary R&D in diabetes and obesity. It will pursue a dual-gene therapy strategy using proprietary bionanotechnological approaches. The rational design of tissue-targeted biore sponsorive gene delivery systems (com completed) will now be accompanied by gene- and protein-silencing in animal models of obesity and diabetes.

PreveCeutical have instructed its research partners to provide final details as to the cost and timeframe to complete these studies in a robust yet expedited manner. PreveCeutical is also approached multiple investment bankers and investors to provide the funding required to complete the preclinical studies. The company anticipencing preclinical studies in early 2024, dependent on the expediencies by which funding and research partners supply/secure the necessary resources, the discussions of which are in the advanced stages with all parties.